Clinical Trial News and Research

RSS

Inhibitex fourth quarter net loss increases to $7.0 million

Inhibitex, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010, and provided an update on recent clinical and corporate developments.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

First U.S. catheter ablation procedure for treatment of AF performed at Mount Sinai

The Mount Sinai Medical Center has become the first hospital in the United States to perform a cardiac catheterization procedure using the TactiCath force-sensing ablation catheter for the treatment of symptomatic paroxysmal atrial fibrillation, or periodic rapid and irregular heartbeats.

11 Mar 2011

New North American survey highlights impact of more complex clinical trials

A new North American survey of 500+ clinical research site professionals documents the impact of more kinds of, and more complex, clinical trials. The survey focused on 3-year trial trends and found key challenges in subject recruitment/retention and tracking and reporting data.

11 Mar 2011

New MEAL study can stop or delay prostate cancer progression

The vegetables most boys wanted to avoid in childhood - such as kale and broccoli - just may be the answer to staving off prostate cancer growth in adulthood. A new clinical trial at UC San Diego Moores Cancer Center will evaluate whether or not a change in diet, reinforced with telephone counseling and exercise, can stop or delay the progression of prostate cancer.

11 Mar 2011

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult population for its proprietary inactivated vaccine against human enterovirus 71, which causes hand, foot, and mouth disease.

10 Mar 2011

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

Preliminary phase I trial results show safety of bone marrow stem cells in children with TBI

Stem cells derived from a patient's own bone marrow were safely used in pediatric patients with traumatic brain injury, according to results of a Phase I clinical trial at The University of Texas Health Science Center at Houston.

10 Mar 2011

Avinger completes patient enrollment in CONNECT trial to treat CTOs linked with PAD

Avinger, Inc., medical device manufacturer of innovative, multi-functional catheters for treating patients with peripheral artery disease, announced that it has successfully completed enrollment in its CONNECT clinical trial.

10 Mar 2011

Columbia fourth quarter total net revenues increase 74% to $14.9 million

Columbia Laboratories, Inc. today reported financial results for the three- and twelve-month periods ended December 31, 2010.

10 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Researcher launches new DBS clinical trial to pinpoint brain activity in depressed people

A top medical researcher at Barrow Neurological Institute at St. Joseph's Hospital in Phoenix, Arizona, has launched a clinical trial to pinpoint brain activity in depressed people by using scientifically designed sad and heartrending photos and music.

10 Mar 2011

U-M participates in national trial for alternative approach to open heart surgery for severe aortic stenosis

The University of Michigan Cardiovascular Center, a leader in heart valve replacement, will participate in a national clinical trial to offer patients a less invasive approach to replacing diseased aortic valves.

10 Mar 2011

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Cell Therapeutics, Inc. today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma following discussions with the U.S. Food and Drug Administration's Division of Hematologic Products.

10 Mar 2011

CRT, ICR sign deal with ZoBio to discover and develop cancer drugs

Cancer Research Technology and The Institute of Cancer Research have signed a deal with Dutch drug discovery company, ZoBio BV, to discover and develop drugs to block a DNA repair target which may play a role in cancer cell survival.

10 Mar 2011

Noninvasive MR-guided focused ultrasound successfully treats essential tremor

A new chapter in medical history opened days ago when noninvasive MR-guided focused ultrasound was used to successfully treat a patient with essential tremor (ET), a progressive neurological disorder that affects millions of people worldwide and causes involuntary shaking of the hands, head, face, eyelids, voice or other muscles.

10 Mar 2011

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline Therapeutics, Inc. today announced that SL-401, the Company's lead compound, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).

10 Mar 2011

PPD introduces new online portal to enhance patient connectivity, improve retention in clinical trials

PPD, Inc. today announced it has launched an innovative online portal linking clinical trial participants with biopharmaceutical companies, physicians and health care resources to enhance patient connectivity and improve retention in clinical trials.

10 Mar 2011

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.

9 Mar 2011

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma announces the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA. This open-labeled trial introduced GRASPA in a first-line treatment for Acute Lymphoblastic Leukemia in patients older than 55 years.

9 Mar 2011

Clinical Trial News and Research

Inhibitex fourth quarter net loss increases to $7.0 million

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

First U.S. catheter ablation procedure for treatment of AF performed at Mount Sinai

New North American survey highlights impact of more complex clinical trials

New MEAL study can stop or delay prostate cancer progression

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Novartis new MS treatment receives Notice of Compliance in Canada

Preliminary phase I trial results show safety of bone marrow stem cells in children with TBI

Avinger completes patient enrollment in CONNECT trial to treat CTOs linked with PAD

Columbia fourth quarter total net revenues increase 74% to $14.9 million

Idera reports $6.0 million net loss for fourth quarter 2010

Researcher launches new DBS clinical trial to pinpoint brain activity in depressed people

U-M participates in national trial for alternative approach to open heart surgery for severe aortic stenosis

CTI announces final pixantrone clinical trial design for treatment of DLBCL

CRT, ICR sign deal with ZoBio to discover and develop cancer drugs

Noninvasive MR-guided focused ultrasound successfully treats essential tremor

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

PPD introduces new online portal to enhance patient connectivity, improve retention in clinical trials

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer